ENDRA Life Sciences Inc. (NDRA)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -6 | -7 | ||||||
| Net profit | $m | -12 | -11 | -13 | -10 | -12 | -7 | -6 | -3 |
| EPS reported | $ | -8.93 | -6.39 | ||||||
| Operating cashflow per share | $ | -6.59 | -3.78 | ||||||
| Capex per share | $ | 0.02 | 2.27 | ||||||
| FCF per share | $ | -6.61 | -6.05 | ||||||
| Free cash flow | $m | -5 | -8 | ||||||
| Net debt | $m | -1 | -1 | ||||||
| Book value equity | $m | 2 | 6 | ||||||
| Book value per share | $ | 2.87 | 2.55 | ||||||
| Number of shares | m | 0.79 | 2.48 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.58 | 0.57 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -0.69 | -0.45 | ||||||
| EV/EBITDA LTM | x | -0.48 | -0.44 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -1.97% | -99.97% | ||||||
| FCF Yield | % | -145.85% | -219.95% | ||||||
| Quality | |||||||||
| ROE | % | -310.93% | -224.80% | ||||||
| ROIC | % | -1.78% | -70.83% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | -100.00% | -100.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -10.56 | -18.27 | ||||||
| Net Debt/EBITDA | x | 0.04 | 0.22 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | +7.56% | ||||||
| Net debt/Equity | x | -0.34 | -0.23 | ||||||
| Gross debt/equity | x | 0.22 | 0.07 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free